Bristol Myers Squibb stories

Oct 23, 2026

Pathos AI raises $237M led by Bristol Myers Squibb, partners on Alzheimer's drug development

AI drug development company Pathos AI announced a $237 million Series E funding round led by Bristol Myers Squibb, reaching a $3 billion valuation. The deal includes a collaboration between Pathos AI, Bristol Myers Squibb, and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders.

Oct 23, 20264 sources

Bristol Myers Squibb and SystImmune breast cancer drug reduces disease progression risk by 59% in phase 3 trial

Bristol Myers Squibb and partner SystImmune announced that their experimental breast cancer treatment izalontamab brengitecan reduced the risk of disease progression or death by 59% compared to standard chemotherapy in patients with advanced HR+/HER2- breast cancer in the phase 3 PANKU-Breast01 study. The late-breaking results are being presented at ESMO 2026.

Oct 23, 20264 sources